Vinflunine (VFL) has been approved in Europe for second-line treatment of metastatic and
advanced urothelial cancer after failure of platin-containing therapy. Since approval, the …

Background There is no standard first-line chemotherapy for advanced urothelial carcinoma
(aUC) in cisplatin-ineligible (cisplatin-unfit) patients. The study assessed the efficacy and …

Strategies to improve cancer care in the field of urothelial carcinoma (UC) in the elderly or in
patients unfit to receive cisplatin treatment are urgently needed. This effort requires …

Once metastatic bladder cancer has progressed to first-line treatment, the number of
therapeutic options is scarce. Among chemotherapeutic agents showing activity in phase II …

Purpose Limited data are available on cabazitaxel pharmacokinetics in patients with renal
impairment. This open-label, multicenter study assessed cabazitaxel in patients with …

Since the inception of Phase I clinical trials in cancer, patients with renal dysfunction have
commonly been excluded from participation because of a poor outlook. Most cancer drugs …

Aims Vinflunine is a novel tubulin‐targeted inhibitor indicated as a single agent for the
treatment of bladder cancers after failure of prior platinum‐based therapy. Its …

Introduction: Vinflunine belongs to the class of vinca alkaloids and acts by disrupting the
microtubule dynamics during cell cycle; this agent is currently available for previously …

The ADDIKD guideline was developed by an expert clinician and academic volunteer
working group using the GRADE approach of analysing available scientific and clinical …

Plants can be distinguished according to their life cycle as annuals, biennials, and
perennials. The success stories of mistletoe, periwinkle, and yew that became drugs in the …